| EPB0251 | Improved viral load suppression with transition to pediatric dolutegravir among ART-experienced children in Kenya and Cote d’Ivoire | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0252 | Improved virologic suppression in children living with HIV under the age of 5 in Tanzania after the initiation of a viremia clinic and pediatric dolutegravir | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0253 | Integrase inhibitor use in children living with HIV in Europe & Thailand over the last decade (2010-2020): uptake and virological response | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0254 | Effectiveness of caregiver mentor directly observed treatment and support model on viral load suppression among children and adolescents living with HIV in Uganda | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0255 | High Prevalence of low level viremia among infants initiated on antiretroviral drugs following Mother to Child Transmission of HIV | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0256 | Dolutegravir in our youngest cohort: follow-up of genotype led antiretroviral optimization in unsuppressed children | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0257 | Viral load suppression in children living with HIV after pediatric dolutegravir optimization in Eswatini | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0258 | High acceptability and preference for pediatric dolutegravir 10mg among children living with HIV in Nigeria at 1- and 6-month follow up, an observational study | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0259 | Outcomes from the Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) study at 6 months in Benin, Nigeria, and Uganda | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0260 | HIV drug resistance trends among 251 treatment experienced children and young adults (0-24 years) | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |